Carisma Therapeutics Inc (CARM)

Mar 31, 2025, 4:30 PM EDT - 25 days ago

Carisma Therapeutics Provides Corporate Updates

Feb 19, 2025, 7:30 AM EST - 2 months ago

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 5, 2025, 7:30 AM EST - 2 months ago

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 9, 2024, 8:30 AM EST - 4 months ago

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

MRNA

Nov 27, 2024, 7:30 AM EST - 5 months ago

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 17, 2024, 7:30 AM EST - 5 months ago

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Nov 8, 2024, 7:30 AM EST - 6 months ago

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

MRNA

Nov 7, 2024, 7:30 AM EST - 6 months ago

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 5, 2024, 9:05 AM EST - 6 months ago

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

MRNA

Oct 30, 2024, 4:30 PM EDT - 6 months ago

Carisma Therapeutics Announces Changes to its Board of Directors

Oct 4, 2024, 9:05 AM EDT - 7 months ago

Carisma Therapeutics Announces Upcoming Presentations at SITC 2024

Sep 10, 2024, 7:30 AM EDT - 8 months ago

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

MRNA

Sep 3, 2024, 7:30 AM EDT - 8 months ago

Carisma Therapeutics to Present at Upcoming Conferences

Aug 8, 2024, 7:30 AM EDT - 9 months ago

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 6, 2024, 7:30 AM EDT - 9 months ago

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

Aug 6, 2024, 7:30 AM EDT - 9 months ago

Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

Jun 27, 2024, 4:30 PM EDT - 10 months ago

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Jun 25, 2024, 7:30 AM EDT - 10 months ago

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

Jun 25, 2024, 7:30 AM EDT - 10 months ago

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

Jun 13, 2024, 4:30 PM EDT - 11 months ago

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

May 30, 2024, 7:30 AM EDT - 11 months ago

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 16, 2024, 7:30 AM EDT - 1 year ago

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

May 9, 2024, 7:30 AM EDT - 1 year ago

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:30 AM EDT - 1 year ago

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

May 6, 2024, 7:30 AM EDT - 1 year ago

Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference

May 2, 2024, 7:30 AM EDT - 1 year ago

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Apr 22, 2024, 4:35 PM EDT - 1 year ago

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 1, 2024, 8:35 AM EDT - 1 year ago

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 21, 2024, 5:00 PM EDT - 1 year ago

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Feb 28, 2024, 7:30 AM EST - 1 year ago

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

Dec 21, 2023, 7:00 AM EST - 1 year ago

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 7:00 AM EST - 1 year ago

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

MRNA

Nov 28, 2023, 7:00 AM EST - 1 year ago

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Nov 22, 2023, 7:30 AM EST - 1 year ago

Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

Nov 9, 2023, 7:30 AM EST - 1 year ago

Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 31, 2023, 9:25 AM EDT - 1 year ago

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Oct 25, 2023, 9:11 AM EDT - 1 year ago

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Carisma Therapeutics to Present at Upcoming Investor Conferences

Sep 1, 2023, 8:30 AM EDT - 1 year ago

Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

Aug 24, 2023, 8:30 AM EDT - 1 year ago

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

Aug 10, 2023, 7:30 AM EDT - 1 year ago

Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 28, 2023, 8:30 AM EDT - 1 year ago

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

Jun 26, 2023, 8:30 AM EDT - 1 year ago

Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes

Jun 14, 2023, 8:30 AM EDT - 2 years ago

Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources

Jun 5, 2023, 7:30 AM EDT - 2 years ago

Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023

May 30, 2023, 4:30 PM EDT - 2 years ago

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

May 11, 2023, 7:30 AM EDT - 2 years ago

Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 8, 2023, 4:30 PM EDT - 2 years ago

Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference

May 5, 2023, 4:30 PM EDT - 2 years ago

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023

Apr 14, 2023, 12:51 PM EDT - 2 years ago

Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting